$193 Million is the total value of Foresite Capital Management IV, LLC's 8 reported holdings in Q1 2023. The portfolio turnover from Q4 2022 to Q1 2023 was 0.0% .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
KNTE | Kinnate Biopharma Inc. | $60,447,769 | +2.5% | 9,671,643 | 0.0% | 31.36% | +24.5% | |
PHVS | Pharvaris N.V. | $26,153,989 | -28.4% | 3,246,926 | 0.0% | 13.57% | -13.0% | |
LYEL | Lyell Immunopharma, Inc. | $23,600,000 | -32.0% | 10,000,000 | 0.0% | 12.24% | -17.4% | |
ACRS | Aclaris Therapeutics, Inc. | $22,716,995 | -48.6% | 2,808,034 | 0.0% | 11.79% | -37.6% | |
KURA | Kura Oncology, Inc. | $22,624,852 | -1.5% | 1,849,947 | 0.0% | 11.74% | +19.7% | |
SNDX | Syndax Pharmaceuticals, Inc. | $18,480,000 | -17.0% | 875,000 | 0.0% | 9.59% | +0.8% | |
CBAY | Cymabay Therapeutics, Inc. | $15,583,460 | +39.1% | 1,787,094 | 0.0% | 8.09% | +69.0% | |
QSI | Quantum-Si Incorporated | $3,117,398 | -3.8% | 1,771,249 | 0.0% | 1.62% | +16.9% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-05-12
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
CymaBay Therapeutics, Inc. | 23 | Q3 2023 | 14.8% |
Aclaris Therapeutics, Inc. | 18 | Q3 2023 | 18.9% |
Kura Oncology, Inc. | 16 | Q3 2023 | 11.7% |
Kinnate Biopharma Inc. | 12 | Q3 2023 | 41.8% |
Myokardia, Inc. | 12 | Q3 2020 | 17.8% |
Pharvaris N.V. | 11 | Q3 2023 | 43.4% |
Cytokinetics Incorporated | 11 | Q2 2021 | 31.6% |
Lyell Immunopharma, Inc. | 10 | Q3 2023 | 29.2% |
Insmed Incorporated | 10 | Q1 2020 | 19.2% |
Biohaven Pharmaceutical Holding Company Ltd. | 9 | Q1 2020 | 14.5% |
View Foresite Capital Management IV, LLC's complete holdings history.
Latest filings
Type | Filed |
---|---|
4 | 2024-04-05 |
13F-HR | 2024-02-13 |
13F-HR | 2023-11-13 |
13F-HR | 2023-08-11 |
13F-HR | 2023-05-12 |
4 | 2023-05-10 |
4 | 2023-02-22 |
13F-HR | 2023-02-13 |
13F-HR | 2022-11-14 |
13F-HR | 2022-08-12 |
View Foresite Capital Management IV, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.